Edition:
India

Extendicare Inc (EXE.TO)

EXE.TO on Toronto Stock Exchange

5.25CAD
10:55pm IST
Change (% chg)

$-0.01 (-0.19%)
Prev Close
$5.26
Open
$5.25
Day's High
$5.30
Day's Low
$5.24
Volume
84,720
Avg. Vol
452,247
52-wk High
$9.60
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Extendicare Posts Q2 Revenue Of $281.9 Mln
Friday, 14 Aug 2020 

Aug 13 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES 2020 SECOND QUARTER RESULTS.EXTENDICARE INC - QTRLY REVENUE UP 4.7% OR $12.7 MILLION TO $281.9 MILLION.EXTENDICARE INC - QTRLY AFFO $0.033 PER BASIC SHARE.  Full Article

Extendicare Q4 Adjusted FFO Per Share C$0.127
Friday, 28 Feb 2020 

Feb 27 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES FOURTH QUARTER AND YEAR END 2019 RESULTS.Q4 ADJUSTED FFO PER SHARE C$0.127.Q4 REVENUE C$290.9 MILLION.QTRLY EARNINGS PER SHARE $0.11.  Full Article

Extendicare Announces Renewal Of Its Normal Course Issuer Bid
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES THE RENEWAL OF ITS NORMAL COURSE ISSUER BID.EXTENDICARE INC - HAS RECEIVED APPROVAL OF TSX TO RENEW ITS NCIB FOR UP TO 8 MILLION OF ITS COMMON SHARES.  Full Article

Extendicare Reports Q3 Adjusted FFO Per Share Of C$0.153
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES 2019 THIRD QUARTER RESULTS.Q3 ADJUSTED FFO PER SHARE C$0.153.Q3 REVENUE C$282.7 MILLION.  Full Article

Extendicare Reports Q2 Revenue C$284 Million
Thursday, 15 Aug 2019 

Aug 14 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES 2019 SECOND QUARTER RESULTS.Q2 ADJUSTED FFO PER SHARE C$0.168.Q2 REVENUE C$284 MILLION.SEES FY 2018 REVENUE C$2.2 MILLION.QTRLY AFFO $0.168 PER BASIC SHARE.Q2 FFO PER SHARE VIEW C$0.13 -- REFINITIV IBES DATA.  Full Article

Extendicare Announces Q1 Adjusted FFO Per Share C$0.142
Wednesday, 15 May 2019 

May 14 (Reuters) - Extendicare Inc ::EXTENDICARE ANNOUNCES 2019 FIRST QUARTER RESULTS.Q1 ADJUSTED FFO PER SHARE C$0.142.Q1 REVENUE ROSE 1 PERCENT TO C$274.3 MILLION.  Full Article

No consensus analysis data available.